TY  - JOUR
A1  - Wranke, Anika
A1  - Heidrich, Benjamin
A1  - Ernst, Stefanie
A1  - Serrano, Beatriz Calle
A1  - Caruntu, Florin Alexandru
A1  - Curescu, Manuela Gabriela
A1  - Yalcin, Kendal
A1  - Gürel, Selim
A1  - Zeuzem, Stefan
A1  - Erhardt, Andreas
A1  - Lüth, Stefan
A1  - Papatheodoridis, George V.
A1  - Bremer, Birgit
A1  - Stift, Judith
A1  - Grabowski, Jan
A1  - Kirschner, Janina
A1  - Port, Kerstin
A1  - Cornberg, Markus
A1  - Falk, Christine S.
A1  - Dienes, Hans-Peter
A1  - Hardtke, Svenja
A1  - Manns, Michael P.
A1  - Yurdaydin, Cihan
A1  - Wedemeyer, Heiner
T1  - Anti-HDV IgM as a marker of disease activity in hepatitis delta
T2  - PLoS One
N2  - Background: Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.
Methods: Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6–12).
Results: Anti-HDV IgM serum levels were negative in 18 (15%), low (OD<0.5) in 76 (63%), and high in 26 (22%) patients of the HIDIT-2 cohort. Anti-HDV IgM were significantly associated with histological inflammatory (p<0.01) and biochemical disease activity (ALT, AST p<0.01). HDV replication was independent from anti-HDV IgM, however, low HBV-DNA levels were observed in groups with higher anti-HDV IgM levels (p<0.01). While high IP-10 (CXCL10) levels were seen in greater groups of anti-HDV IgM levels, various other antiviral cytokines were negatively associated with anti-HDV IgM. Associations between anti-HDV IgM and ALT, AST, HBV-DNA were confirmed in the independent cohort. Clinical endpoints occurred in 26 anti-HDV IgM positive patients (39%) but in only one anti-HDV IgM negative individual (9%; p = 0.05).
Conclusions: Serum anti-HDV IgM is a robust, easy-to-apply and relatively cheap marker to determine disease activity in hepatitis delta which has prognostic implications. High anti-HDV IgM levels may indicate an activated interferon system but exhausted antiviral immunity.
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/35087
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-350876
SN  - 1932-6203
N1  - Copyright: © 2014 Wranke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
VL  - 9
IS  - (7):e101002
PB  - PLoS
CY  - Lawrence, Kan.
ER  -